Gastroenterology
Volume 137, Issue 3 , Pages 873-884.e1 , September 2009

Decline in Male Sexual Desire, Function, and Satisfaction During and After Antiviral Therapy for Chronic Hepatitis C

  • Lorna M. Dove

      Affiliations

    • Division of Gastroenterology and Hepatology, Department of Internal Medicine, New York Presbyterian Medical Center, New York, New York
    • ,
  • Raymond C. Rosen

      Affiliations

    • New England Research Institutes, Watertown, Massachusetts
    • ,
  • Darmendra Ramcharran

      Affiliations

    • Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
    • ,
  • Abdus S. Wahed

      Affiliations

    • Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
    • ,
  • Steven H. Belle

      Affiliations

    • Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
    • Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
    • ,
  • Robert S. Brown

      Affiliations

    • Division of Gastroenterology and Hepatology, Department of Internal Medicine, New York Presbyterian Medical Center, New York, New York
    • ,
  • Jay H. Hoofnagle

      Affiliations

    • Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland
    • Corresponding Author InformationReprint requests Address requests for reprints to: Jay H. Hoofnagle, MD, Liver Diseases Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 31 Center Drive, Room 9A27, Bethesda, Maryland 20892
    • ,
  • Virahep-C Study Group

Received 10 October 2008 ,Accepted 29 May 2009.

References 

  1. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–714
  2. Strader DB, Wright T, Thomas DL, et al. American Association for the Study of Liver Diseases (Diagnosis, management, and treatment of hepatitis C). Hepatology. 2004;39:1147–1171
  3. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006;130:231–264
  4. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin therapy for chronic hepatitis C. N Engl J Med. 2006;355:2444–2451
  5. Muir AJ, Bornstein JD, Killenberg PGAtlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265–2271
  6. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with chronic hepatitis C, genotype 1. Gastroenterology. 2006;131:470–477
  7. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(Suppl 1):S237–S244
  8. Peginterferon alfa-2a (for injection) (Product information). Nutley, NJ: Roche Pharmaceuticals; 2009;
  9. Peginterferon alfa-2b (powder for injection) (Product information). Kenilworth, NJ: Schering Corporation; 2009;
  10. Fattovich G, Giustina G, Favarato S, et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 1996;24:38–47
  11. Danoff A, Khan O, Wan DW, et al. Sexual dysfunction is highly prevalent among men with chronic hepatitis C virus infection and negatively impacts health-related quality of life. Am J Gastroenterol. 2006;101:1235–1243
  12. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology. 2007;45:80–87
  13. Fontana RJ, Kleiner DE, Bilonick R, et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology. 2006;44:925–935
  14. Rosen HR, Weston SJ, Im K, et al. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy. Hepatology. 2007;46:350–358
  15. Donlin MJ, Cannon NA, Yao E, et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. J Virol. 2007;81:8211–8224
  16. Taylor MW, Tsukahara T, Brodsky L, et al. Changes in gene express during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol. 2007;81:3391–3401
  17. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22:696–699
  18. Rosen RC, Riley A, Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997;49:822–830
  19. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States (Prevalence and predictors). JAMA. 1999;281:537–544
  20. Ware JE, Kosinski M, Keller SK. SF-36® physical and mental health summary scales: a user's manual. Boston, MA: The Health Institute; 1994;
  21. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401
  22. Clark CH, Mahoney JS, Clark DJ, et al. Screening for depression in a hepatitis C population;the reliability and validity of the Center for Epidemiologic Studies Depression Scale (CES-D). J Adv Nurs. 2002;40:361–369
  23. Rabe-Hesketh S, Skrondal A. Multilevel and longitudinal modeling using STATA. College Station, TX: Stata Press; 2005;
  24. Williams R. Generalized ordered logit/partial proportional odds models for ordinal dependent variables. Stata J. 2006;6:58–82
  25. Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357:762–774
  26. Barqawi AB, Myers JB, O'Donnell C, et al. The effect of α-blocker and 5α-reductase inhibitor intake on sexual health in men with lower urinary tract symptoms. BJU International. 2007;100:853–857
  27. Cappelleri JC, Rosen RC. The sexual health inventory for men (SHIM): a 5-year review of research and clinical experience. Int J Impot Res. 2005;17:307–319

 Conflicts of interest The authors disclose no conflicts.

 Funding This study was funded as a cooperative agreement by the National Institute of Diabetes and Digestive and Kidney Diseases with cosupport from the National Center on Minority Health and Health Disparities and the Intramural Research Program of the National Cancer Institute with further support under a Cooperative Research and Development Agreement with Roche Laboratories, Inc. Supported by grants U01 DK60329, U01 DK60340, U01 DK60324, U01 DK60344, U01 DK60327, U01 DK60335, U01 DK60352, U01 DK60342, U01 DK60345, U01 DK60309, U01 DK60346, U01 DK60349, and U01 DK60341 and National Center for Research Resources General Clinical Research Centers Program grants M01 RR00645 (New York Presbyterian), M02 RR000079 (University of California, San Francisco), M01 RR16500 (University of Maryland), M01 RR000042 (University of Michigan), and M01 RR00046 (University of North Carolina). Peginterferon, ribavirin, HCV RNA detection assays, and funds for ancillary studies were provided by Roche Pharmaceutics through a Cooperative Research and Development Agreement between Roche and the National Institute of Diabetes and Digestive and Kidney Diseases. NCT Trial Number: NCT00038974.

PII: S0016-5085(09)00919-6

doi: 10.1053/j.gastro.2009.05.060

Gastroenterology
Volume 137, Issue 3 , Pages 873-884.e1 , September 2009

Article Tools

* Image Usage & Resolution